Mode
Text Size
Log in / Sign up
Phase 2 N=530 Randomized Quadruple-blind Treatment

Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction

ST Elevation Myocardial Infarction · Inflammatory Response · Myocardial Reperfusion Injury · Myocardial Injury

Enrolled (actual)
530
Serious AEs
22.1%
Results posted
Mar 2026
Primary outcome: Primary: Final Infarct Size — 5; 6 % of LV

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Methylprednisolone (Drug); Isotonic saline (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Thomas Engstrom
Primary completion
Jan 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Final Infarct Size
5; 6
SECONDARY
CMR Efficacy: The Extent of MVO
0.3; 0.6
SECONDARY
CMR Efficacy: The Extent of Haemorrhage
54; 63
SECONDARY
CMR Efficacy: MVO
92; 115
SECONDARY
CMR Efficacy: Area at Risk
28; 30
SECONDARY
CMR Efficacy: MSI
55; 50
SECONDARY
CMR Efficacy: LVEF
28; 30
SECONDARY
Peak Troponin-T
2205; 2840
SECONDARY
All-cause Mortality
7; 13
SECONDARY
Safety: Incidence of Adverse Events
11; 14

Summary

The overall primary objective of the PULSE-MI trial is to test the hypothesis that administration of single-dose glucocorticoid pulse therapy in the pre-hospital setting reduces final infarct size in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI)

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years including fertile women (It is not possible to perform a pregnancy test (HCG urine test) in the pre-hospital setting. However, methylprednisolone is not contraindicated in pregnant women).
  • Acute onset of chest pain with 12 hours.
  • Known allergy to glucocorticoid or known mental illness with maniac or psychotic episodes.
  • Patients with previous acute myocardial infarction (AMI) in the assumed culprit artery.
  • Previous coronary artery bypass graft (CABG).
  • Unable to read and understand Danish.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05462730). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search